MARKET

PYXS

PYXS

Pyxis Oncology, Inc.
NASDAQ
3.010
0.000
0.00%
After Hours: 3.100 +0.09 +2.99% 19:57 08/14 EDT
OPEN
2.990
PREV CLOSE
3.010
HIGH
3.080
LOW
2.862
VOLUME
703.83K
TURNOVER
--
52 WEEK HIGH
5.55
52 WEEK LOW
0.9700
MARKET CAP
251.06M
P/E (TTM)
-2.1472
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating Reiterated on MICVO’s Differentiated Profile and 2026 Data Catalysts; $6 Price Target Maintained
TipRanks · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS)
TipRanks · 1d ago
Pyxis Oncology (PYXS) Gets a Buy from Wells Fargo
TipRanks · 1d ago
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)
TipRanks · 2d ago
Pyxis Oncology Q2 EPS $(0.40) Misses $(0.35) Estimate
Benzinga · 2d ago
Pyxis Oncology GAAP EPS of -$0.40 misses by $0.05
Seeking Alpha · 2d ago
*Pyxis Oncology 2Q Research and Development Expenses $16.1M >PYXS
Dow Jones · 2d ago
More
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Webull offers Pyxis Oncology Inc stock information, including NASDAQ: PYXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PYXS stock methods without spending real money on the virtual paper trading platform.